Preclinical investigations on broccoli-derived sulforaphane for the treatment of ophthalmic disease

Faith A A Kwa; Bang V Bui; Bruce R Thompson; Lauren N Ayton

doi:10.1016/j.drudis.2023.103718

Preclinical investigations on broccoli-derived sulforaphane for the treatment of ophthalmic disease

Drug Discov Today. 2023 Sep;28(9):103718. doi: 10.1016/j.drudis.2023.103718. Epub 2023 Jul 17.

Authors

Faith A A Kwa¹, Bang V Bui², Bruce R Thompson³, Lauren N Ayton⁴

Affiliations

¹ Department of Health Sciences and Biostatistics, School of Health Sciences, Swinburne University of Technology, Hawthorn, VIC 3122, Australia. Electronic address: fkwa@swin.edu.au.
² Department of Optometry & Vision Sciences, Faculty Medicine, Dentistry & Health Sciences, The University of Melbourne, VIC 3010, Australia.
³ School of Health Sciences, Faculty Medicine, Dentistry & Health Sciences, The University of Melbourne, VIC 3010, Australia.
⁴ Department of Optometry & Vision Sciences, Faculty Medicine, Dentistry & Health Sciences, The University of Melbourne, VIC 3010, Australia; Department of Surgery (Ophthalmology), Faculty Medicine, Dentistry & Health Sciences, The University of Melbourne, VIC 3010, Australia; Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC 3002, Australia.

PMID: 37467881
DOI: 10.1016/j.drudis.2023.103718

Abstract

Vision loss causes a significant burden on individuals and communities on a financial, emotional and social level. Common causes include age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and retinitis pigmentosa (RP; also known as 'rod-cone dystrophy'). As the population continues to grow and age globally, an increasing number of people will experience vision loss. Hence, there is an urgent need to develop therapies that can curb early pathological events. The broccoli-derived compound, sulforaphane (SFN), is reported to have multiple health benefits and modes of action. In this review, we outline the preclinical findings on SFN in ocular diseases and discuss the future clinical testing of this compound.

Keywords: age-related macular degeneration; diabetic retinopathy; glaucoma; retinitis pigmentosa; sulforaphane.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Brassica*
Humans
Isothiocyanates / therapeutic use
Macular Degeneration* / drug therapy
Retinitis Pigmentosa* / therapy
Vision Disorders

Substances

sulforaphane
Isothiocyanates